Hikal Ltd

Hikal, a small-cap company in the Pharmaceuticals & Drugs sector, experienced significant trading activity on February 5, 2025, outperforming its peers. The stock's current price exceeds its short-term moving averages, while it lags behind in the medium term. Recent performance metrics indicate a mixed outlook compared to the broader market.

Hikal has reported flat financial performance for Q3 FY24-25, with a notable adjustment in its evaluation score. The company maintains a commendable debt-equity ratio of 0.64, reflecting prudent financial management. However, it faces challenges with declining profit before and after tax, alongside rising interest costs. Non-operating income has reached a five-quarter high, though its sustainability is uncertain.

Hikal has recently been added to MarketsMOJO's list following a revision in its score, reflecting the company's robust performance and market trends. The stock has demonstrated a strong upward trajectory, outperforming both its sector and the broader market, indicating potential growth opportunities for investors.

Hikal has recently experienced a notable adjustment in its evaluation, reflecting its strong market performance and upward price momentum. The stock has been added to MarketsMOJO's list, highlighting its impressive returns and resilience against market volatility. Investors are keenly observing Hikal's continued growth in the pharmaceutical sector.

Hikal, a midcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on November 29th, 2024. The stock has consistently outperformed the sector, with a 6.6% increase in returns in the past two days. Hikal's strong presence in the midcap market and consistent performance in the pharmaceutical industry have contributed to its success.

Hikal, a midcap pharmaceutical company, has shown a positive trend in its stock performance on November 29, 2024. The stock has gained 6.68%, outperforming the sector by 5.41% and hitting a new 52-week high. According to MarketsMOJO, the current stock call for Hikal is 'Hold', indicating a potential for further growth.

Hikal, a midcap pharmaceutical and drug company, has been in the news for its strong performance in the stock market. Its share price reached a 52-week high on November 18, 2024, and has been consistently gaining in the past few days. The stock is currently trading above its moving averages and has outperformed the market in the past year. Investors should conduct their own research before making any investment decisions.

Hikal, a midcap pharmaceutical and drug company, reported a flat financial performance in the second quarter of FY24-25 with a score of -1, showing improvement from -23 in the last three months. The company's PAT has grown by 20.06% and it has a low Debt-Equity Ratio and high DPR. However, there are concerns regarding increased interest costs and declining Operating Cash Flow. MarketsMOJO recommends holding positions on the stock.

Hikal, a midcap pharmaceutical and drug company, saw a 5.34% increase in its stock price on November 14, 2024. According to MarketsMOJO, the stock is currently rated as 'Hold', indicating a positive but cautious outlook. The stock has consistently performed well, trading higher than its moving averages and outperforming the market.

Hikal, a smallcap pharmaceutical and drug company, has seen a surge in its stock price, reaching a 52-week high of Rs 410.9 on November 13, 2024. The stock is currently trading at 0.96% below its high and has outperformed the sector by 4.72%. Hikal has also shown strong growth in the past year, outperforming the Sensex.

Hikal, a smallcap pharmaceutical company, has been downgraded to a 'Sell' by MarketsMOJO due to poor long-term growth and negative financial results. Despite technical factors showing a mildly bullish trend, the company's ROCE and operating profit are at their lowest. Institutional investors have shown interest, but caution is advised for investors based on current data.

Hikal, a smallcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its improved technical trend and positive MACD and KST factors. However, the stock is currently trading at a discount compared to its historical valuations and has shown poor long-term growth and negative results. Institutional investors have increased their stake, but investors should monitor the company's performance closely.

Hikal, a smallcap pharmaceutical company, has received a 'Sell' rating from MarketsMOJO due to its poor long-term growth and weak financial performance. The company's annual operating profit growth rate over the last 5 years was -6.61%, with a significant decrease in profits and net sales in June 2024. Its low ROCE and operating profit to interest ratio raise concerns about its ability to generate profits. While the stock is currently in a mildly bullish range, its technical factors may not be enough to offset its financial performance. Hikal's attractive valuation may be a red flag for potential investors, and the majority of its shareholders being promoters could indicate a lack of interest from external investors.

Hikal, a smallcap pharmaceutical and drug company, has received a 'Hold' rating from MarketsMOJO due to its bullish trend and attractive valuation. However, the company's profits have declined and it has shown poor growth over the past 5 years. Majority shareholders are promoters, which may have influenced the upgrade.

On October 14th, 2024, Hikal, a smallcap pharmaceutical and drug company, saw a positive performance with a 7.18% increase in stock, outperforming the sector by 6.19%. This marks the second consecutive day of gains for Hikal, with a total increase of 6.23% in the past two days. Its moving averages are higher than its 5-day, 50-day, 100-day, and 200-day moving averages, but lower than its 20-day moving average. In comparison to the Sensex, Hikal's performance has been significantly better, with a 7.18% increase compared to Sensex's 0.70% increase on October 14th. In the past month, Hikal's performance has been -7.67%, while the Sensex has seen a -1.13% decrease. Currently recommended as a 'Sell' by MarketsMOJO, Hikal continues to show potential for growth as a smallcap company in the pharmaceutical and drug industry.

Hikal, a smallcap pharmaceutical and drug company, has been downgraded to a 'Sell' by MarketsMOJO due to poor long-term growth and negative financial results. The company's profits and net sales have decreased significantly, resulting in a 20.83% underperformance in the market. Despite attractive valuation and majority ownership by promoters, the stock has been downgraded based on its financial performance and market trends.

Hikal, a smallcap pharmaceutical and drug company, has seen a surge in its stock price, reaching a 52-week high on September 18th, 2024. The stock has outperformed the sector by 2.28% and is currently trading higher than its moving averages. Despite high volatility, the company has shown consistent gains and a strong performance in the past year. MarketsMOJO has given a 'Hold' call for the stock, based on its current performance and market conditions. Investors should conduct thorough research and seek professional advice before making any decisions.

Hikal, a smallcap pharmaceutical and drug company, has been performing well in the market, with its stock reaching a 52-week high on September 12, 2024. The stock has shown consecutive gains for the past 2 days and is trading higher than its moving averages, indicating a positive trend. Hikal's strong performance and efficient management make it a promising player in the smallcap market.

Hikal, a smallcap pharmaceutical and drug company, has seen a surge in its stock price, reaching a 52-week high on September 11, 2024. The stock has outperformed its sector by 4.7% and has shown high volatility. Its strong financials and market position have led to a bullish trend, with a remarkable growth of 28.21% in the past year. MarketsMOJO has given a 'Hold' call, suggesting investors to hold onto their positions. Overall, Hikal's consistent growth and positive outlook make it a promising player in the industry.